Name: Glial fibrillary acidic protein (GFAP) - BioCentury Target Profiles - BCIQ
Creator: Biocentury

Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

Explore BCIQ profiles by entering a target name.

BioCentury | Jun 21, 2024

Product Development

Rare Disease Spotlight: Rare form of dementia a gateway indication for PGRN?

Half a dozen programs aim to boost PGRN expression in the CNS. They are targeting FTD-GRN as a proving ground

BioCentury | Jun 7, 2024

Regulation

Lilly raises the bar in Alzheimer’s, but complicates path to approval

FDA’s questions for advisory committee center on patient subgroups, and whether and when to end amyloid mAb treatment

BioCentury | Sep 11, 2023

Guest Commentary

We’re at a pivot point in Alzheimer’s drug development, and we mustn’t let history slow us down

BioCentury | Apr 26, 2023

Regulation

In ascending to the ranks of surrogate endpoint, NfL stands to galvanize ALS clinical trials and accelerate validation of the next biomarkers

BioCentury | Nov 10, 2021

Product Development

Argues plasma Aβ42/40 falls short as a method for identifying patients for clinical trials

BioCentury | Jan 17, 2020

Preclinical News

BioCentury | Sep 13, 2019

Clinical News